



**MEETING OF THE BORDERS FORMULARY COMMITTEE HELD  
ON WEDNESDAY 27<sup>th</sup> OCTOBER 2021 @ 12:30pm via MICROSOFT TEAMS**

**MINUTE**

Present: Keith Maclure (KMacl) (Chair); Liz Leitch (LL); Dr Paul Neary (PN); Fiona Grant (FG); Dr Nicola Henderson (NH); Rhona Morrison; Gillian Donaldson (GD); Rhona Morrison (RM)

1. **Apologies:** Alison Wilson (Keith Maclure chairing meeting); Adam Groves (CT3 Junior Doctors Changeover)

Item No.	Situation ; Background ; Assessment	Recommendation	Person Responsible	Timescale
<b>2</b>	<b>Welcome and any declarations of interest: - None</b>			
2.1	East Regional Formulary Committee Declaration of Interest form was issued with agenda and it to be completed by all members and returned to email address on form. BFC discussed the new East Region meeting times – because timings have changed from BFC - they clash with consultant clinics and also Primary Care Prescribing Group which will mean that NH will miss PCPG and PN clinics would have to be cancelled to attend. LL to feedback to ERF project team but it is unlikely that this will be able to be changed.		ALL  LL	After BFC meeting
<b>3</b>	Minute from BFC meeting 25 <sup>th</sup> August 2021 was read and approved as an accurate record of the meeting.	Upload to internet	KW	01/11/21
<b>4</b>	<b>Matters Arising From Previous Minute:</b>			
4.1	BFC Decision for Guselkumab (Tremfya) was not approved at August BFC and Dr A Tan asked for this to be reconsidered. BFC discussed the application at length, reasons for previously not approving; SMC advice and restrictions; BFC also discussed the cost information included in application sent again by Dr Tan. Drug would be 2 <sup>nd</sup> line biological; number of options available and reasons for this were discussed. After much debate it was agreed to approve as an additional option for the service.	BFC Approved : For Specialist Use only as an additional option to current formulary options Letter to applicant	  KW	  01/11/21
4.2	SCA Guanfacine - no current update was available.			
4.3	Welcomed to new BFC member Adam Groves, CT3 Junior Doctor changeover, who was unavailable for this meeting but is available to attend ERF meetings going forward.	BFC Noted		
<b>5</b>	<b>New Medicine Applications &amp; Non Formulary Requests:</b>			
5.1	<b>NMA Casirivimab+Imdevimab</b>	BFC Noted Approval: For		

	Applicant: Kirsten Thomson on behalf of Dr Garrioch and Dr Mackay; Clinical Director;; Indication: Use in covid treatment; Generic Name: Casirivimab+Imdevimab; Brand Name: Ronapreve; Dosage: 2.4g (1.2g casirivimab + 1.2g Imdevimab). A single IV dose is given. Cost: £ included in application; Number of patients in first year: Projected increase in patients: This was approved virtually and here for discussion, BFC heard that there is good evidence for use. BFC requested a policy/protocol for use from the applicants as there are a range of options available for patients and supporting documentation is required for medical staff working on the covid ward.	Specialist Use Only Protocol required to be updated. Letter to applicant Protocol to ADTC for approval	KW LL	01/11/21 15/11/21
5.2	<b>NMA Fremanezumab (Ajovy)</b> Applicant: Dr Myles Connor; Clinical Director: Dr John O'Donnell; Indication: For prophylaxis of migraine in adults who have at least four migraines per month. SMC restriction for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventative treatments.; Generic Name: Fremanezumab; Brand Name: Ajovy Dosage: see application; Cost: included in application; Number of patients in first year: 3-5; Projected increase in patients: None. Application was summarised; in line with SMC advice with evidence available and trials well tolerated. Costs were outlined and a good summary of where this drug would be used was included with application. Discussed use of previous drug and the advantage of using this as second choice as appropriate. BFC discussed and requested feedback from Dr Connor on first choice drug Erenumab – to be requested in approval letter.	BFC Approved : For Specialist Use Only Letter to applicant Include request for response on first choice Erenumab patients.	KW	01/11/21
5.3	<b>NMA Inclisiran</b> Dr J O'Donnell emailed regarding this NMA as he did not want to support use in the Borders; preferring to wait for feedback from other clinician colleagues in other health board areas. There are two other injectable drugs on formulary, prescriptions go through healthcare at home – estimated 10 patients – BFC asked for feedback on these drugs as well. It was commented that this drug is less frequent injection and a good benefit to patients and JOD to be asked when the educational number crunching will be done.	BFC to write to Dr O D to ask when this can be reconsidered for application.	KW	01/11/21
5.4	<b>NFR Epidyolex / Cannabidiol</b> was discussed; decision and minute in NFR folder	Letter to applicant	KW	01/11/21
5.5	<b>NFR Finasteride</b> was discussed; decision and minute in NFR folder	Letter to applicant	KW	01/11/21
5.6	<b>NFR Psyllium husk capsules</b> was discussed; decision and minute in NFR folder	Letter to applicant	KW	
<b>6</b>	<b>Scottish Medicines Consortium (SMC) Decisions</b>			
6.1	SMC – verbal update from PN including information regarding the decision on Osemertinib.	BFC Noted		
6.2	SMC Decisions updated August and September 2021	BFC Noted		
6.3	Included in the SMC Decisions doc above - PASAG - Paediatric Licence Extensions	BFC Noted		
<b>7</b>	<b>Borders Joint Formulary:</b>			
7.1	No formulary updates			
<b>8</b>	<b>East Region Formulary:</b>			
8.1	East Region Formulary update – September 2021 – information included was outlined for BFC.	BFC Noted		

8.2	East Regional Formulary governance groups members and meeting dates and ERFC meeting agenda and papers for information.	BFC Noted		
8.3	BFC received an update on GP engagement to East Regional Formulary working groups. There are 6 groups and all have now representation from GPs. Listed below along with consultant, specialist nurse and pharmacist representation where known. Dr N Henderson – GI and Skin; Dr E Longworth – Antimicrobial; Dr Anurag Yadav; Cardiology – Dr P Neary, Gillian Donaldson, Allison Carruthers; Dr K Cathrow – Endocrinology – Dr O Herlihy, Linda Ker; Dr F Morton – Respiratory – Dr T Mackay, Emma Dodd, Elaine Hancock. NHS Borders are the only Board who have Specialist Nurses sitting on the groups and we are pleased ER teams have agreed to this as their specialist knowledge is very valuable. GPs for other groups will be appointed and for each a form is completed by LL to go to GP Sub Group for approval for funding. BFC agreed that any NFRs to be picked up or discussed could be done with short meetings and email where necessary.	BFC Noted		
8.4	BFC reviewed the FAFs for East Regional Formulary applications which will be available to Borders, Fife and Lothian consultants to make applications for use of new SMC approved medications. This will entail liaising with colleagues from other Boards and LL will initially support this process. As this process will take much longer than the current responsive application and approval process through BFC and ADTC, the committee discussed approving drugs with SMC approval for use within NHS Borders through the Non Formulary Request route to ensure that patients have access to SMC approved drugs when appropriate. BFC approved this and also updating forms and flow charts on Intranet to reflect changes.	BFC Approved NFR application route Update intranet Update flowchart	KW KW LL	08/11/21 08/11/21
<b>9</b>	<b>Other Items for Approval</b>			
9.1	NHS Lothian recommendation on anticoagulation in cancer patients with VTE – a draft Departmental Memo for the introduction of Apixaban. BFC discussed this change in choice of anticoagulant for patients with solid tumour and developed DVT or PE. Currently patients receive 5 days of Dalteparin and then switch to Edoxaban. Change involves switching from Edoxaban to Apixaban as a formulary amendment that would require an update to our guidelines and also education for prescribers. Use of LMWH for 5 days commented on. BFC agreed to support this change and asked PN and LL to take forward changing guidelines and ensuring prescribers are educated on the change. This will also be reviewed by Anti Coagulation Committee at their next scheduled meeting.	BFC Approved Inform A Christie Change guidance and ensure education in place	LL LL PN	01/11/21 After Anti-coag meeting
<b>10</b>	<b>For Information and Noting</b>			
10.1	Anticoagulation Committee meeting minute – 21 <sup>st</sup> September 2021	BFC Noted		
10.2	Wound Formulary Group meeting action note - 26 <sup>th</sup> August 2021	BFC Noted		
10.3	Tissue Viability Group – no recent meeting			
10.4	IV Therapy Group meeting minute - 8 <sup>th</sup> September 2021	BFC Noted		
10.5	Lothian Formulary Committee meeting minutes – 25 <sup>th</sup> August 2021	BFC Noted		
<b>11</b>	<b>A.O.C.B. –</b>			

11.1	NFR Opicapone was discussed; decision and minute in NFR folder	Letter to applicant	KW	01/11/21
Next Meeting: There will be no more meetings of Borders Formulary Committee – members will attend the East Regional Formulary committee / governance groups in future. Dates and calendar invites have been issued.				